tbuckley/cabot-search huggingface dataset:
Abstract 3078: CD44 mRNA stability is regulated by RNA binding protein HuR in ovarian cancer cells
Authors: Karl E. Miletti-Gonzalez, Christine L. Hostetter, Abhilash K. Ravindranath, Neelakandan Muthukumaran, Judith C. Keen, Lorna Rodriguez-Rodriguez
Journal: Cancer Research (2011)

Abstract CD44, a major hyaluronic acid (HA) receptor, is involved in cell migration, metastasis and tumor progression. While in normal ovarian epithelium CD44 is not expressed, ovarian carcinoma cells express multiple CD44 isoforms as the tumor progresses and eventually CD44 expression is abrogated in advanced ovarian cancer metastatic sites. We as well as others have observed that the levels of CD44 mRNA transcript not always correspond to the CD44 protein expression levels. This observation suggests that CD44 is post-transcriptionally regulated. To test this hypothesis we first analyzed the CD44 3’ untranslated region (3’ UTR) sequence and found numerous AU-rich elements (ARE) in this region. Some of these sequences are known HuR binding site consensus sequences. HuR is an RNA binding protein that is known to stabilize transcripts. HuR is expressed in the nucleus and is transported to the cytoplasm where it functions as an mRNA stabilizer. We performed mRNA half-life experiments that showed a two-fold reduction in the stability of CD44 transcript in siHuR transfected ovarian cancer cells. Consistent with this result, treatment of these cells with inhibitors of DNA methylation and histone deacetylation (i.e., 5-azacytidine and Trichostatin A, respectively) known to diminish the presence of HuR in the cytoplasm, also decreased the stability of CD44 mRNA. Western blot analysis showed the expected reduction in cytoplasmic HuR as well as down-regulation in CD44 protein expression. A direct interaction of HuR with the CD44 3’ UTR was detected by biotin pulldown assays. These results indicate that HuR posttranscriptionally stabilizes the expression of CD44 in the cytoplasm. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3078. doi:10.1158/1538-7445.AM2011-3078
A CASE OF CAT-BITE FEVER
Authors: G. E. Beaumont, A. M. Gill
Journal: BMJ (1935)

Cases of cat-bite fever are rare, particularly in this country, although a short note recording an instance of the disease was published by Collier in the British Medical Journal in 1924.1It is generally agreed nowadays that rat-bite fever and catbite fever are one and the same disease, and a case of rat-bite fever ac-
The Physical and Psychological Sequelae of Torture
Authors: Anne E. Goldfeld
Journal: JAMA (1988)

We present a review of the international literature on the medical and psychological effects of torture. Our review reveals that certain tortures and their physical and emotional sequelae are more prevalent than previously appreciated. They include the common occurrence of sexual violence during the torture of women and female adolescents and the high frequency of head injury and associated neuropsychiatric consequences. We recommend the use of standardized diagnostic criteria in the evaluation of patients who have survived torture; this will facilitate patient care and the documentation of human rights violations.
Angiographic Stenosis Progression and Coronary Events in Patients With ‘Stabilized’ Unstable Angina
Authors: Lijia Chen, Michael R. Chester, Simon Redwood, Jian Huang, Edward Leatham, Juan Carlos Kaski
Journal: Circulation (1995)

Background Recent studies suggest that angiographically complex coronary stenoses are associated with an adverse short-term outcome. It is not known, however, if this applies to unstable angina patients who stabilize on medical therapy. Methods and Results We prospectively studied 85 consecutive patients with unstable angina who stabilized on medical therapy but were found to require angioplasty for treatment of obstructive coronary disease. Angiography was carried out at admission, and patients were restudied 8±4 months (mean±SD) after the first angiogram. Ischemia-related stenoses were identified and classified as “complex” (irregular borders, overhanging edges, or thrombus) or “smooth” (absence of complex features). Stenosis progression (≥20% diameter reduction or new total occlusion) was assessed by automated edge detection. At initial angiography, there were 198 stenoses (≥50%, 102), of which 85 (54 complex and 31 smooth) were ischemia related. At restudy, 21 ischemia-related stenoses and 8 non–ischemia-related stenoses progressed (25% versus 7%, P =.001). Seventeen of the 21 ischemia-related stenoses that progressed developed into total occlusion compared with 3 of the 8 non–ischemia-related stenoses ( P =.02). Changes in average stenosis severity and in absolute stenosis diameter were significantly larger in ischemia-related stenoses than in non–ischemia-related stenoses ( P =.03). Eighteen (34%) complex stenoses progressed, compared with 3 (10%) smooth lesions ( P =.02). During follow-up, 1 patient died (myocardial infarction) and 25 patients had nonfatal coronary events that were associated with progression of ischemia-related stenoses in 14 (56%). Conclusions In unstable angina patients who stabilize medically, subsequent short-term stenosis progression and coronary events are common. The unstable coronary lesion (particularly complex stenoses) is often not stabilized and will continue to progress over the ensuing months.
Abstract LB-370: A placental growth factor variant unable to recognize VEGFR-1 inhibits VEGF-dependent tumor angiogenesis via heterodimerization
Authors: Sandro De Falco, Valeria Tarallo, Onofrio Capasso, Loredana Vesci, Maria Teresa Esposito, Lucio Pastore, Augusto Orlandi, Claudio Pisano
Journal: Cancer Research (2010)

Abstract Angiogenesis is one of the crucial events for cancer development and growth. Two members of vascular endothelial growth factor (VEGF) family, VEGF-A and placental growth factor (PlGF), which are able to heterodimerize if co-expressed in the same cell, are both required for pathological angiogenesis. We generated a PlGF1 variant, named PlGF1-DE in which the residues Asp72 and Glu73 were substituted with Ala. PlGF1-DE is unable to bind and activate VEGFR-1 but can heterodimerize with VEGF (J. Biol. Chem., 279: 43929-43939, 2004). Here we demonstrate that overexpression of PlGF1-DE variant in tumor cells by adenoviral delivery or stable transfection significantly reduced the production of VEGF homodimer via heterodimerization, leading to a strong inhibition of xenograft tumor growth and neoangiogenesis, as well as significant reduction of vessel size, vessel stabilization by smooth muscle cells and monocyte-macrophage infiltration. PlGF1-DE/VEGF heterodimer, differently from wild type heterodimer able to induce VEGFR-1 dimerization as well as VEGFR-1/R-2 heterodimerization and activation, failed to induce receptors phosphorylation demonstrating that co-expression of PlGF1-DE variant in VEGF-producing cells effectively sequestered active VEGF, biasing toward the generation of a non-functional heterodimer. Conversely, overexpression of PlGF1wt, while reducing VEGF homodimer production comparably to PlGF1-DE variant through the generation of VEGF/PlGF heterodimer, did not inhibit tumor growth and vessel density compared to controls, but induced an increase of vessel size, vessel stabilization and monocyte-macrophage infiltration. The ability of PlGF and VEGF-A to heterodimerize represents a successful strategy to inhibit VEGF-dependent angiogenesis. The PlGF1-DE variant, and not PlGF1wt as previously reported, acts as a ‘dominant negative’ of VEGF molecule and is a new candidate for anti-angiogenic gene therapy in cancer treatment. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr LB-370.
QL-21 * SPIRITUAL WELL-BEING AND ITS ASSOCIATION WITH HEALTH-RELATED QUALITY OF LIFE IN PRIMARY BRAIN TUMOR PATIENTS
Authors: D. Randazzo, M. Affronti, E. Lipp, F. McSherry, J. Herndon, C. Flahiff, E. Miller, S. Woodring, M. Freeman, P. Healy, J. Minchew, S. Boulton, A. Desjardins, T. Ranjan, G. Vlahovic, H. Friedman, K. Peters
Journal: Neuro-Oncology (2014)

Spirituality has been shown to impact patients' attitudes and decisions about treatment and end-of-life care when coping with chronic illnesses such as cancer. Previous studies have documented that health-related quality of life (HRQoL) and spiritual well-being are positively correlated, but little is known about the phenomenon in the primary brain tumor population. Therefore, we sought to measure spiritual well-being in primary brain tumor patients and evaluate whether it was associated with HRQoL. Data collected within the Preston Robert Tisch Brain Tumor Center at Duke as part of the PRoGREss registry between 12/16/2013 and 2/28/2014 were queried retrospectively. In addition to demographic and clinical information, data was obtained from patient reported outcome questionnaires including Functional Assessment of Cancer Therapy-Brain Cancer (FACT-Br) with a score range from 0-184 and Functional Assessment of Chronic Illness Therapy-Spiritual Well-Being (FACIT-Sp12) with a score range from 0-48. Correlation analyses were performed with the Pearson correlation coefficient. For this study, 845 subjects were identified. Mean age was 49.8 (SD = 13.5) years and 54.6% were male, 56.8% married, and 34.1% college educated. Median score for FACT-Br Total was 135.9 with range from 40.8 to 184 and median score for FACIT-Sp12 was 38.0 with range from 8.0 to 48.0. A significant positive correlation existed between scores on FACT-Br and FACIT-Sp12 with r = 0.636 (p <0.0001). Similar results were seen for correlations between FACT-Br total score and FACIT-Sp12 subscales (Faith r = 0.338, p < 0.0001 and Meaning/Peace r = 0.712, p < 0.0001). These results highlight the relationship between spirituality and HRQoL in the brain tumor population and suggest that implementing strategies to measure and encourage spiritual well-being may be one avenue to improve HRQoL.
A new role for a psychiatrist?
Authors: R. Morriss
Journal: BMJ (1995)

One of the most challenging aspects of the current NHS is the proliferation of roles that a doctor now has to undertake. Some of these are managerial and financial and some are new clinical challenges, such as keyhole surgery. Here is a new clinical role for a community psychiatrist—namely, healing rifts between gangs of aggressive young men in two neighbourhoods. Previously I had thought that community based police, youth workers, social workers, or possibly the saintly Dr Jack Kerruish, the GP in Peak Practice, might reasonably be left to heal rifts between gangs; never before had I thought that this would be …
Authors' reply to Winkler and Ravnskov
Authors: R. Micha, D. Mozaffarian
Journal: BMJ (2014)

We agree with Winkler that the interpretation of dietary data requires appropriate perspective, context, and recognition of strengths and limitations, as is true for any scientific research.1 2 But Winkler’s concerns reflect only a partial understanding of the strengths and limitations of various nutritional assessment methods. 

The interpretation and validity of individual level dietary data depend on the dietary assessment tool used (such as diet records, diet recalls, semi-quantitative food frequency questionnaires, tissue biomarkers) as well as the level of …
Ohio Epileptic Asylum.
Authors: W. McKinley
Journal: JAMA (1893)

The following communication has been received, addressed "To the State and county officers and the public:" I am advised by the Board of Trustees of the Ohio Hospital for Epileptics, that they are about ready to open for the admission of 250 male patients, but are not yet provided with the proper information to enable them to enumerate and classify the applicants for admission. The probate court of each county has proper blank forms for application, and it is earnestly desired that all who seek the care of this institution shall call upon the probate judge and fill out these blanks and forward to Dr. H. C. Rutter, Manager, Gallipolis, O., at once. Very truly,
Certification in Diagnostic Laboratory Immunology
Authors: REBECCA H. BUCKLEY
Journal: Annals of Internal Medicine (1988)

Editorials1 March 1988Certification in Diagnostic Laboratory ImmunologyREBECCA H. BUCKLEY, M.D., Allen P. Kaplan, M.D., Sheldon M. Wolff, M.D., Max D. Cooper, M.D.REBECCA H. BUCKLEY, M.D.Search for more papers by this author, Allen P. Kaplan, M.D.Search for more papers by this author, Sheldon M. Wolff, M.D.Search for more papers by this author, Max D. Cooper, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-108-3-458 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe second examination for certification of special qualification in diagnostic laboratory immunology will be held 7 October 1988 in St. Louis. The examination, which will assess the competence of internists and pediatricians conducting diagnostic immunologic tests, is analogous to the special qualification examination in immunopathology of the American Board of Pathology. It is open to physicians certified by the American Board of Internal Medicine, the American Board of Pediatrics, or the American Board of Allergy and Immunology who also have training or (until 1990) significant laboratory experience in diagnostic laboratory immunology.Physicians taking the examination are expected to be concerned... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: REBECCA H. BUCKLEY, M.D.; Allen P. Kaplan, M.D.; Sheldon M. Wolff, M.D.; Max D. Cooper, M.D.Affiliations: American Board of Pediatrics PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byWhat Is A Clinical Immunologist?Diagnostic laboratory immunology: A subspecialty that encompasses clinical as well as laboratory immunology 1 March 1988Volume 108, Issue 3Page: 458-459KeywordsAllergy and immunologyDiagnostic medicineImmunologyImmunopathologyPediatricsResearch laboratories ePublished: 1 December 2008 Issue Published: 1 March 1988 PDF downloadLoading ...
No Pretending Not to Know
Authors: Douglas L. Brown
Journal: JAMA (1988)

"Send her on to ultrasound," I tell the obstetric resident. He had scanned the patient himself and hadn't been able to get the BPD measurement. He and I both have the same worst fear. I have some slim hope that maybe the baby's head is just very low in the pelvis and difficult to image, but we are long overdue for an anencephalic. As I read the patient's chart I learn she is at approximately 36 weeks' gestation based on an earlier ultrasound, one that we did. Panic. Did we miss the diagnosis before? I pull the early ultrasound; she was only eight weeks at that time and the scan was normal, even in retrospect. I don't expect to diagnose anencephaly by ultrasound at eight weeks. Mrs Jackson changes into a hospital gown and lies on the table beside the scanner. I can tell from her face that she is
Effect of Oral Zinc Therapy on Gonadal Function in Hemodialysis Patients
Authors: SUDESH K. MAHAJAN
Journal: Annals of Internal Medicine (1982)

Zinc deficiency may account for the persistence of gonadal dysfunction in a majority of uremic men despite adequate dialysis. Twenty stable patients having hemodialysis three times a week completed a double-blind trial using either 50 mg of elemental zinc as zinc acetate (10 patients) or placebo (10 patients), orally. At the end of the 6-month study period, a significant increase in the mean (+/- SE) plasma zinc (75 +/- 2 micrograms/dL to 100 +/- 2 micrograms/dL, p less than 0.001), serum testosterone (2.8 +/- 0.3 ng/dL to 5.2 +/- 0.5 ng/mL, p less than 0.001), and sperm count (30 +/- 3 million/mL to 63 +/- 5 million/mL, p less than 0.001) occurred in the zinc-treated group, but not in those receiving the placebo. The zinc-treated group also had a significant fall in serum luteinizing hormone (92 +2- 10 mIU/mL to 49 +/- 26 mIU/mL, p less than 0.005) and follicle stimulating hormone (45 +/- 9 mIU/mL to 25 +/- 7 mIU/mL, p less than 0.05), not seen in the placebo group. Patients receiving zinc had an improvement in potency, libido, and frequency of intercourse not found in the placebo group. These results suggest that zinc deficiency is a reversible cause of gonadal dysfunction in patients having regular hemodialysis.
Amoebic Encephalitis Due to Sappinia diploidea
Authors: Benjamin B. Gelman, Shariq J. Rauf, Remi Nader, Vselevod Popov, Joanna Borkowski, Gregory Chaljub, Haring W. Nauta, Govinda S. Visvesvara
Journal: JAMA (2001)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Twilight Zone: Astute Medical Technologist Vanishes Unacknowledged, Leaving Smear
Authors: Arthur S. Levy
Journal: JAMA (1985)

To the Editor.—  The PHOTO/ESSAY, Histoplasmosis Diagnosed on a Peripheral Blood Smear From a Patient With AIDS,1 was submitted by five physicians, each of whom will add the citation to his curriculum vitae. Good for them.  But what of the real hero, the  medical  who made the diagnosis? Should not the astute medical technologist who made this report possible have been offered authorship? Has the technologist received any acknowledgment such as a commendation in his or her personnel record? Such a commendation would be helpful when the time comes for that astute medical technologist to search for another, more rewarding job.
Hypoglycemic Episodes and Risk of Dementia in Older Patients With Type 2 Diabetes Mellitus
Authors: Rachel A. Whitmer, Andrew J. Karter, Kristine Yaffe, Charles P. Quesenberry, Joseph V. Selby
Journal: JAMA (2009)

Although acute hypoglycemia may be associated with cognitive impairment in children with type 1 diabetes, no studies to date have evaluated whether hypoglycemia is a risk factor for dementia in older patients with type 2 diabetes.To determine if hypoglycemic episodes severe enough to require hospitalization are associated with an increased risk of dementia in a population of older patients with type 2 diabetes followed up for 27 years.A longitudinal cohort study from 1980-2007 of 16,667 patients with a mean age of 65 years and type 2 diabetes who are members of an integrated health care delivery system in northern California.Hypoglycemic events from 1980-2002 were collected and reviewed using hospital discharge and emergency department diagnoses. Cohort members with no prior diagnoses of dementia, mild cognitive impairment, or general memory complaints as of January 1, 2003, were followed up for a dementia diagnosis through January 15, 2007. Dementia risk was examined using Cox proportional hazard regression models, adjusted for age, sex, race/ethnicity, education, body mass index, duration of diabetes, 7-year mean glycated hemoglobin, diabetes treatment, duration of insulin use, hyperlipidemia, hypertension, cardiovascular disease, stroke, transient cerebral ischemia, and end-stage renal disease.At least 1 episode of hypoglycemia was diagnosed in 1465 patients (8.8%) and dementia was diagnosed in 1822 patients (11%) during follow-up; 250 patients had both dementia and at least 1 episode of hypoglycemia (16.95%). Compared with patients with no hypoglycemia, patients with single or multiple episodes had a graded increase in risk with fully adjusted hazard ratios (HRs): for 1 episode (HR, 1.26; 95% confidence interval [CI], 1.10-1.49); 2 episodes (HR, 1.80; 95% CI, 1.37-2.36); and 3 or more episodes (HR, 1.94; 95% CI, 1.42-2.64). The attributable risk of dementia between individuals with and without a history of hypoglycemia was 2.39% per year (95% CI, 1.72%-3.01%). Results were not attenuated when medical utilization rates, length of health plan membership, or time since initial diabetes diagnosis were added to the model. When examining emergency department admissions for hypoglycemia for association with risk of dementia (535 episodes), results were similar (compared with patients with 0 episodes) with fully adjusted HRs: for 1 episode (HR, 1.42; 95% CI, 1.12-1.78) and for 2 or more episodes (HR, 2.36; 95% CI, 1.57-3.55).Among older patients with type 2 diabetes, a history of severe hypoglycemic episodes was associated with a greater risk of dementia. Whether minor hypoglycemic episodes increase risk of dementia is unknown.
Role of dietary sulphate in the regulation of methanogenesis in the human large intestine.
Authors: S U Christl, G R Gibson, J H Cummings
Journal: Gut (1992)

Hydrogen produced during colonic fermentation may be excreted, or removed by H2 consuming bacteria such as methanogenic and sulphate reducing bacteria. In vitro, sulphate reducing bacteria compete with methanogenic bacteria for hydrogen when sulphate is present. In this study the hypothesis that sulphate in the diet could alter CH4 production in vivo has been tested. Six methane excreting volunteers were fed a low sulphate diet (1.6 mmol/d) for 34 days with the addition of 15 mmol sodium sulphate from days 11-20. Breath methane was measured and viable counts and metabolic activities of methanogenic bacteria and sulphate reducing bacteria determined in faeces. Whole gut transit time and daily stool weight were also measured. When sulphate was added to the diet, breath methane excretion decreased in three of the subjects while faecal sulphate reduction rates rose from 7.5 (0.5) to 20.3 (4.3) nmol SO4 reduced/h/g faeces. Sulphate reducing bacteria, which were not detected during the control diet, were found and viable counts of methanogenic bacteria fell from 10(7)-10(9)/g faeces to 10(6)/g. Methanogenic counts and breath CH4 recovered after sulphate addition was stopped. No change was found in the other three subjects. Faecal weights and transit times were not different between study periods. It is concluded that methanogenesis is regulated by dietary sulphate if sulphate reducing bacteria are present. Dietary sulphate may allow growth of sulphate reducing bacteria which inhibit the growth of methanogenic bacteria. This may explain the absence of CH4 in the breath of many people in western populations.